Vipul Jairath1, Guangyong Zou2, Claire E Parker3, John K Macdonald3, Mahmoud H Mosli4, Reena Khanna3, Lisa M Shackelton5, Margaret K Vandervoort5, Turki AlAmeel6, Mohammad Al Beshir6, Majid AlMadi7, Talal Al-Taweel8, Nathan S S Atkinson9, Sujata Biswas9, Thomas P Chapman9, Parambir S Dulai10, Mark A Glaire11, Daniel Hoekman12, Andreas Koutsoumpas9, Elizabeth Minas13, Mark A Samaan14, Simon Travis9, Geert D'Haens15, Barrett G Levesque10, William J Sandborn10, Brian G Feagan16. 1. Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, UK Robarts Research Institute, University of Western Ontario, London, ON, Canada Department of Medicine, University of Western Ontario, London, ON, Canada vipul.jairath@robartsinc.com. 2. Robarts Research Institute, University of Western Ontario, London, ON, Canada Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON, Canada. 3. Robarts Research Institute, University of Western Ontario, London, ON, Canada Department of Medicine, University of Western Ontario, London, ON, Canada. 4. Robarts Research Institute, University of Western Ontario, London, ON, Canada Department of Medicine, University of Western Ontario, London, ON, Canada Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. 5. Robarts Research Institute, University of Western Ontario, London, ON, Canada. 6. Department of Medicine, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia. 7. Division of Gastroenterology, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia. 8. Haya Al-Habeeb Gastroenterology Center, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait. 9. Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, UK. 10. Robarts Research Institute, University of Western Ontario, London, ON, Canada Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA. 11. Division of Medical Sciences, University of Oxford, Oxford, UK. 12. Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands. 13. Department of Geratology, Oxford University Hospitals NHS Trust, Oxford, UK. 14. Department of Gastroenterology, Guy's and St Thomas' Hospital NHS Trust, London, UK. 15. Robarts Research Institute, University of Western Ontario, London, ON, Canada Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands. 16. Robarts Research Institute, University of Western Ontario, London, ON, Canada Department of Medicine, University of Western Ontario, London, ON, Canada Department of Medicine, University of Western Ontario, London, ON, Canada.
Abstract
BACKGROUND AND AIMS: Minimisation of the placebo responses in randomised controlled trials [RCTs] is essential for efficient evaluation of new interventions. Placebo rates have been high in ulcerative colitis [UC] clinical trials, and factors influencing this are poorly understood. We quantify placebo response and remission rates in UC RCTs and identify trial design factors influencing them. METHODS: MEDLINE, EMBASE, and the Cochrane Library were searched from inception through April 2014 for placebo-controlled trials in adult patients with UC of a biological agent, corticosteroid, immunosuppressant, or aminosalicylate. Data were independently doubly extracted. Quality was assessed using the Cochrane risk of bias tool. RESULTS: In all, 51 trials [48 induction and 10 maintenance phases] were identified. Placebo response and remission rates were pooled according to random-effects models, and mixed-effects meta-regression models were used to evaluate effects of study-level characteristics on these rates. Pooled estimates of placebo remission and response rates for induction trials were 10% (95% confidence interval [CI] 7-13%) and 33% [95% CI 29-37%], respectively. Corresponding values for maintenance trials were 19% [95% CI 11-30%] and 22% [95% CI 17-28%]. Trials enrolling patients with more active disease confirmed by endoscopy [endoscopy subscore ≥ 2] were associated with lower placebo rates. Conversely, placebo rates increased with increasing trial duration and number of study visits. CONCLUSIONS: Objective assessment of greater disease activity at trial entry by endoscopy lowered placebo rates, whereas increasing trial duration and more interactions with healthcare providers increased placebo rates. These findings have important implications for design and conduct of clinical trials.
BACKGROUND AND AIMS: Minimisation of the placebo responses in randomised controlled trials [RCTs] is essential for efficient evaluation of new interventions. Placebo rates have been high in ulcerative colitis [UC] clinical trials, and factors influencing this are poorly understood. We quantify placebo response and remission rates in UC RCTs and identify trial design factors influencing them. METHODS: MEDLINE, EMBASE, and the Cochrane Library were searched from inception through April 2014 for placebo-controlled trials in adult patients with UC of a biological agent, corticosteroid, immunosuppressant, or aminosalicylate. Data were independently doubly extracted. Quality was assessed using the Cochrane risk of bias tool. RESULTS: In all, 51 trials [48 induction and 10 maintenance phases] were identified. Placebo response and remission rates were pooled according to random-effects models, and mixed-effects meta-regression models were used to evaluate effects of study-level characteristics on these rates. Pooled estimates of placebo remission and response rates for induction trials were 10% (95% confidence interval [CI] 7-13%) and 33% [95% CI 29-37%], respectively. Corresponding values for maintenance trials were 19% [95% CI 11-30%] and 22% [95% CI 17-28%]. Trials enrolling patients with more active disease confirmed by endoscopy [endoscopy subscore ≥ 2] were associated with lower placebo rates. Conversely, placebo rates increased with increasing trial duration and number of study visits. CONCLUSIONS: Objective assessment of greater disease activity at trial entry by endoscopy lowered placebo rates, whereas increasing trial duration and more interactions with healthcare providers increased placebo rates. These findings have important implications for design and conduct of clinical trials.
Authors: Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar Journal: Gut Date: 2011-01-05 Impact factor: 23.059
Authors: P Marteau; C S Probert; S Lindgren; M Gassul; T G Tan; A Dignass; R Befrits; G Midhagen; J Rademaker; M Foldager Journal: Gut Date: 2005-07 Impact factor: 23.059
Authors: William J Sandborn; Jean-Frederic Colombel; Bruce E Sands; Paul Rutgeerts; Stephan R Targan; Remo Panaccione; Brian Bressler; Karl Geboes; Stefan Schreiber; Richard Aranda; Sheila Gujrathi; Allison Luo; Yun Peng; Luisa Salter-Cid; Stephen B Hanauer Journal: Gastroenterology Date: 2012-04-12 Impact factor: 22.682
Authors: G R Lichtenstein; G L Gordon; S Zakko; U Murthy; S Sedghi; R Pruitt; K Merchant; A Shaw; E Bortey; W P Forbes Journal: Aliment Pharmacol Ther Date: 2010-08-18 Impact factor: 8.171
Authors: W J Sandborn; B E Sands; D C Wolf; J F Valentine; M Safdi; S Katz; K L Isaacs; L D Wruble; J Katz; D H Present; E V Loftus; F Graeme-Cook; D J Odenheimer; S B Hanauer Journal: Aliment Pharmacol Ther Date: 2003-06-01 Impact factor: 8.171
Authors: Simon P L Travis; Silvio Danese; Limas Kupcinskas; Olga Alexeeva; Geert D'Haens; Peter R Gibson; Luigi Moro; Richard Jones; E David Ballard; Johan Masure; Matteo Rossini; William J Sandborn Journal: Gut Date: 2013-02-22 Impact factor: 23.059
Authors: Jonathan Athayde; Sarah C Davies; Claire E Parker; Leonardo Guizzetti; Christopher Ma; Reena Khanna; Brian G Feagan; Vipul Jairath Journal: Dig Dis Sci Date: 2018-07-11 Impact factor: 3.199
Authors: Hans Herfarth; Edward L Barnes; John F Valentine; John Hanson; Peter D R Higgins; Kim L Isaacs; Susan Jackson; Mark T Osterman; Kristen Anton; Anastasia Ivanova; Millie D Long; Christopher Martin; Robert S Sandler; Bincy Abraham; Raymond K Cross; Gerald Dryden; Monika Fischer; William Harlan; Campbell Levy; Robert McCabe; Steven Polyak; Sumona Saha; Emmanuelle Williams; Vijay Yajnik; Jose Serrano; Bruce E Sands; James D Lewis Journal: Gastroenterology Date: 2018-06-30 Impact factor: 22.682
Authors: Vipul Jairath; G Y Zou; Claire E Parker; John K MacDonald; Turki AlAmeel; Mohammad Al Beshir; Majid A Almadi; Talal Al-Taweel; Nathan Ss Atkinson; Sujata Biswas; Thomas Chapman; Parambir S Dulai; Mark A Glaire; Daniël R Hoekman; Andreas Koutsoumpas; Elizabeth Minas; Mahmoud H Mosli; Mark Samaan; Reena Khanna; Simon Travis; Geert D'Haens; William J Sandborn; Brian G Feagan Journal: Cochrane Database Syst Rev Date: 2017-09-08
Authors: Matthew R Henn; Edward J O'Brien; Liyang Diao; Brian G Feagan; William J Sandborn; Curtis Huttenhower; Jennifer R Wortman; Barbara H McGovern; Sherry Wang-Weigand; David I Lichter; Meghan Chafee; Christopher B Ford; Patricia Bernardo; Peng Zhao; Sheri Simmons; Amelia D Tomlinson; David N Cook; Roger J Pomerantz; Bharat K Misra; John G Auninš; Michele Trucksis Journal: Gastroenterology Date: 2020-08-04 Impact factor: 22.682
Authors: Mark A Samaan; Polychronis Pavlidis; Jonathan Digby-Bell; Emma L Johnston; Angad Dhillon; Ramesh Paramsothy; Abisoye O Akintimehin; Lucy Medcalf; Guy Chung-Faye; Patrick DuBois; Ioannis Koumoutsos; Nick Powell; Simon H C Anderson; Jeremy Sanderson; Bu' Hussain Hayee; Peter M Irving Journal: Frontline Gastroenterol Date: 2017-10-11